InVivo Therapeutics has announced the resignation of Steven McAllister from the position of chief financial officer effective December 31, 2016. According to a company release, he has indicated he will be transitioning to a new opportunity at a privately-held medical device company.
In connection with his departure, the company has appointed Melanie Morel-Ferris to assume the responsibilities and title of interim chief financial officer, effective January 1, 2016. In this capacity, she will serve the role of the company’s principal financial officer and principal accounting officer.
Morel-Ferris has served as the company’s controller since May, 2016. Prior to joining InVivo, Morel-Ferris served as the corporate controller of Astrodyne TDI, an electrical manufacturing company from July 2014 to May 2016. Prior to that, Morel-Ferris served as the associate director of corporate accounting of ARIAD Pharmaceuticals, a drug development company, from January 2014 to July 2014, and as a senior accounting manager at ARIAD from January 2011 to December 2013. Morel-Ferris, who began her career at Deloitte, received a Bachelor of Arts from Assumption College, Worcester, USA, and is a Certified Public Accountant.